Last 12 months
Inside the activity.
0 purchase rows · 66 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 4 |
| Dec 2025 | 0 | 1 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 21 |
| Apr 2026 | 0 | 1 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 5 |
| Jul 2026 | 0 | 3 |
| Aug 2026 | 0 | 22 |
| Sep 2026 | 0 | 8 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 02, 2019 Filed Dec 3, 2019 01:29 UTC |
COOKE MICHAEL P.Chief Scientific Officer
|
Salecommon stock | 2,500 | $13.21 | $33,036.00 |
DisclosureSEC source: 0001562180-19-005782 · primarydocument.xml · nonDerivative · entry 3 COOKE MICHAEL P. · CIK 0001741288 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 240,523 F3 · price: This transaction was executed in multiple trades at prices ranging from $12.75 to $13.35. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request by the staff of the U.S. Securities and Exchange Commission, the issuer or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 02, 2019 Filed Dec 3, 2019 01:29 UTC |
COOKE MICHAEL P.Chief Scientific Officer
|
Salecommon stock | 1,373 | $13.31 | $18,279.30 |
DisclosureSEC source: 0001562180-19-005782 · primarydocument.xml · nonDerivative · entry 2 COOKE MICHAEL P. · CIK 0001741288 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 243,023 F2 · price: This transaction was executed in multiple trades at prices ranging from $13.25 to $13.39. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request by the staff of the U.S. Securities and Exchange Commission, the issuer or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 02, 2019 Filed Dec 3, 2019 01:29 UTC |
COOKE MICHAEL P.Chief Scientific Officer
|
Salecommon stock | 3,627 | $12.74 | $46,204.72 |
DisclosureSEC source: 0001562180-19-005782 · primarydocument.xml · nonDerivative · entry 1 COOKE MICHAEL P. · CIK 0001741288 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 244,396 F1 · price: This transaction was executed in multiple trades at prices ranging from $12.25 to $13.20. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request by the staff of the U.S. Securities and Exchange Commission, the issuer or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 20, 2019 Filed Nov 26, 2019 01:52 UTC |
COOKE MICHAEL P.Chief Scientific Officer
|
Salecommon stock | 5,000 | $12.00 | $60,000.00 |
DisclosureSEC source: 0001562180-19-005711 · primarydocument.xml · nonDerivative · entry 1 COOKE MICHAEL P. · CIK 0001741288 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 248,023 Read SEC document |
| November 01, 2019 Filed Nov 2, 2019 00:02 UTC |
COOKE MICHAEL P.Chief Scientific Officer
|
Salecommon stock | 5,000 | $10.67 | $53,333.50 |
DisclosureSEC source: 0001562180-19-005307 · primarydocument.xml · nonDerivative · entry 1 COOKE MICHAEL P. · CIK 0001741288 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 253,023 F1 · price: This transaction was executed in multiple trades at prices ranging from $10.35 to $10.715. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request by the staff of the U.S. Securities and Exchange Commission, the issuer or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 01, 2019 Filed Oct 3, 2019 20:50 UTC |
COOKE MICHAEL P.Chief Scientific Officer
|
SaleCommon Stock | 5,000 | $10.01 | $50,064.00 |
DisclosureSEC source: 0001562180-19-005101 · primarydocument.xml · nonDerivative · entry 1 COOKE MICHAEL P. · CIK 0001741288 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 258,023 F1 · price: This transaction was executed in multiple trades at prices ranging from $9.515 to $10.22. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request by the staff of the U.S. Securities and Exchange Commission, the issuer or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 19, 2019 Filed Sep 19, 2019 20:26 UTC |
COOKE MICHAEL P.Chief Scientific Officer
|
Salecommon stock | 1,656 | $12.00 | $19,872.00 |
DisclosureSEC source: 0001562180-19-004884 · primarydocument.xml · nonDerivative · entry 1 COOKE MICHAEL P. · CIK 0001741288 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 263,023 F1 · kind: This trade is pursuant to an active 10b5-1 plan. Read SEC document |
| September 12, 2019 Filed Sep 16, 2019 22:36 UTC |
COOKE MICHAEL P.Chief Scientific Officer
|
Salecommon stock | 844 | $12.00 | $10,128.00 |
DisclosureSEC source: 0001562180-19-004830 · primarydocument.xml · nonDerivative · entry 1 COOKE MICHAEL P. · CIK 0001741288 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 264,679 F1 · kind: This trade is pursuant to an active 10b5-1 plan. Read SEC document |
| September 03, 2019 Filed Sep 4, 2019 21:06 UTC |
COOKE MICHAEL P.Chief Scientific Officer
|
SaleCommon Stock | 5,000 | $10.11 | $50,531.00 |
DisclosureSEC source: 0001562180-19-004630 · primarydocument.xml · nonDerivative · entry 1 COOKE MICHAEL P. · CIK 0001741288 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 265,523 F1 · kind: This trade is pursuant to an active 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $9.81 to $10.225. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request by the staff of the U.S. Securities and Exchange Commission, the issuer or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 01, 2019 Filed Aug 1, 2019 20:14 UTC |
COOKE MICHAEL P.Chief Scientific Officer
|
Salecommon stock | 2,500 | $13.41 | $33,522.50 |
DisclosureSEC source: 0001562180-19-004122 · primarydocument.xml · nonDerivative · entry 2 COOKE MICHAEL P. · CIK 0001741288 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 270,523 F1 · kind: This trade is pursuant to an active 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $13.40 to $13.4325. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request by the staff of the U.S. Securities and Exchange Commission, the issuer or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 01, 2019 Filed Aug 1, 2019 20:14 UTC |
COOKE MICHAEL P.Chief Scientific Officer
|
Salecommon stock | 5,000 | $13.42 | $67,108.50 |
DisclosureSEC source: 0001562180-19-004122 · primarydocument.xml · nonDerivative · entry 1 COOKE MICHAEL P. · CIK 0001741288 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 273,023 F1 · kind: This trade is pursuant to an active 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $13.40 to $13.4325. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request by the staff of the U.S. Securities and Exchange Commission, the issuer or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 01, 2019 Filed Jul 2, 2019 14:51 UTC |
COOKE MICHAEL P.Chief Scientific Officer
|
Salecommon stock | 2,500 | $14.42 | $36,050.50 |
DisclosureSEC source: 0001562180-19-003734 · primarydocument.xml · nonDerivative · entry 2 COOKE MICHAEL P. · CIK 0001741288 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 278,023 F1 · kind: This trade is pursuant to an active 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $14.20 to $14.80. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request by the staff of the U.S. Securities and Exchange Commission, the issuer or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 01, 2019 Filed Jul 2, 2019 14:51 UTC |
COOKE MICHAEL P.Chief Scientific Officer
|
Salecommon stock | 5,000 | $14.39 | $71,932.50 |
DisclosureSEC source: 0001562180-19-003734 · primarydocument.xml · nonDerivative · entry 1 COOKE MICHAEL P. · CIK 0001741288 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 280,523 F1 · kind: This trade is pursuant to an active 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $14.20 to $14.80. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request by the staff of the U.S. Securities and Exchange Commission, the issuer or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 21, 2019 Filed Jun 24, 2019 16:02 UTC |
ISACSON CHRISTINA K.Chief Business Officer
|
SaleCommon Stock | 5,415 | $16.07 | $87,019.05 |
DisclosureSEC source: 0001562180-19-003624 · primarydocument.xml · nonDerivative · entry 1 ISACSON CHRISTINA K. · CIK 0001741281 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,116 F1 · kind: This trade is pursuant to an active 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $16.00 to $16.22. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request by the staff of the U.S. Securities and Exchange Commission, the issuer or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 21, 2019 Filed Jun 24, 2019 20:02 UTC |
GARDNER JASONDirector · See Remarks
|
SaleCommon Stock | 12,331 | $15.11 | $186,321.41 |
DisclosureSEC source: 0001562180-19-003623 · primarydocument.xml · nonDerivative · entry 2 GARDNER JASON · CIK 0001741286 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 349,212 F1 · kind: This trade is pursuant to an active 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $15.10 to $15.23. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request by the staff of the U.S. Securities and Exchange Commission, the issuer or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 20, 2019 Filed Jun 24, 2019 21:04 UTC |
McGeorge AnneDirector
|
GrantStock Option (Right to Buy) · Derivative | 36,377 | $0.00 Strike: $14.94 | $0.00 |
DisclosureSEC source: 0000899243-19-017955 · doc4.xml · derivative · entry 1 McGeorge Anne · CIK 0001779934 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,377 Underlying: Common Stock · 36,377 shares Expires 2029-06-19 F1 · derivative.exercise_date: This option shall vest and become exercisable over three years, with 33% of this option vesting on June 20, 2020, and the remainder vesting in 24 equal monthly installments thereafter. Read SEC document |
| June 20, 2019 Filed Jun 24, 2019 20:02 UTC |
GARDNER JASONDirector · See Remarks
|
SaleCommon Stock | 1,669 | $15.10 | $25,201.90 |
DisclosureSEC source: 0001562180-19-003623 · primarydocument.xml · nonDerivative · entry 1 GARDNER JASON · CIK 0001741286 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 361,543 F1 · kind: This trade is pursuant to an active 10b5-1 plan. Read SEC document |
| June 17, 2019 Filed Jun 18, 2019 21:18 UTC |
COOKE MICHAEL P.Chief Scientific Officer
|
Salecommon stock | 7,500 | $13.90 | $104,267.25 |
DisclosureSEC source: 0001562180-19-003585 · primarydocument.xml · nonDerivative · entry 1 COOKE MICHAEL P. · CIK 0001741288 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 285,523 F1 · kind: This trade is pursuant to an active 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $13.72 to $14.20. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 07, 2019 Filed Jun 11, 2019 21:13 UTC |
Albers Jeffrey W.Director
|
GrantStock Option (Right to Buy) · Derivative | 18,188 | $0.00 Strike: $13.40 | $0.00 |
DisclosureSEC source: 0000899243-19-016422 · doc4.xml · derivative · entry 1 Albers Jeffrey W. · CIK 0001638474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,188 Underlying: Common Stock · 18,188 shares Expires 2029-06-06 F1 · derivative.exercise_date: This option shall vest and become exercisable in full upon the earlier to occur of (a) June 7, 2020 or (b) the next annual meeting of the Issuer's stockholders. Read SEC document |
| June 07, 2019 Filed Jun 11, 2019 21:13 UTC |
RONNEBERG AMY LDirector
|
GrantStock Option (Right to Buy) · Derivative | 18,188 | $0.00 Strike: $13.40 | $0.00 |
DisclosureSEC source: 0000899243-19-016421 · doc4.xml · derivative · entry 1 RONNEBERG AMY L · CIK 0001380292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,188 Underlying: Common Stock · 18,188 shares Expires 2029-06-06 F1 · derivative.exercise_date: This option shall vest and become exercisable in full upon the earlier to occur of (a) June 7, 2020 or (b) the next annual meeting of the Issuer's stockholders. Read SEC document |
| June 07, 2019 Filed Jun 11, 2019 21:12 UTC |
Scadden DavidDirector
|
GrantStock Option (Right to Buy) · Derivative | 18,188 | $0.00 Strike: $13.40 | $0.00 |
DisclosureSEC source: 0000899243-19-016419 · doc4.xml · derivative · entry 1 Scadden David · CIK 0001707715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,188 Underlying: Common Stock · 18,188 shares Expires 2029-06-06 F1 · derivative.exercise_date: This option shall vest and become exercisable in full upon the earlier to occur of (a) June 7, 2020 or (b) the next annual meeting of the Issuer's stockholders. Read SEC document |
| June 07, 2019 Filed Jun 11, 2019 21:07 UTC |
Booth BruceDirector
|
GrantStock Option (Right to Buy) · Derivative | 18,188 | $0.00 Strike: $13.40 | $0.00 |
DisclosureSEC source: 0000899243-19-016414 · doc4.xml · derivative · entry 1 Booth Bruce · CIK 0001451612 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,188 Underlying: Common Stock · 18,188 shares Expires 2029-06-06 F1 · derivative.exercise_date: This option shall vest and become exercisable in full upon the earlier to occur of (a) June 7, 2020 or (b) the next annual meeting of the Issuer's stockholders. F2 · ownership.direct: This option was granted to The Reporting Person, a director of the Issuer. The proceeds of any sale of shares of common stock issued to The Reporting Person upon exercise of this option will be transferred to Atlas Venture Life Science Advisors, LLC and as such, The Reporting Person disclaims ownership of such securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| June 07, 2019 Filed Jun 11, 2019 21:06 UTC |
Daniel Thomas ODirector
|
GrantStock Option (Right to Buy) · Derivative | 18,188 | $0.00 Strike: $13.40 | $0.00 |
DisclosureSEC source: 0000899243-19-016413 · doc4.xml · derivative · entry 1 Daniel Thomas O · CIK 0001538894 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,188 Underlying: Common Stock · 18,188 shares Expires 2029-06-06 F1 · derivative.exercise_date: This option shall vest and become exercisable in full upon the earlier to occur of (a) June 7, 2020 or (b) the next annual meeting of the Issuer's stockholders. Read SEC document |
| June 07, 2019 Filed Jun 11, 2019 21:03 UTC |
Byers BlakeDirector
|
GrantStock Option (Right to Buy) · Derivative | 18,188 | $0.00 Strike: $13.40 | $0.00 |
DisclosureSEC source: 0000899243-19-016410 · doc4.xml · derivative · entry 1 BYERS BLAKE · CIK 0001741840 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,188 Underlying: Common Stock · 18,188 shares Expires 2029-06-06 F1 · derivative.exercise_date: This option shall vest and become exercisable in full upon the earlier to occur of (a) June 7, 2020 or (b) the next annual meeting of the Issuer's stockholders. Read SEC document |
| June 07, 2019 Filed Jun 11, 2019 21:00 UTC |
Borisy AlexisDirector
|
GrantStock Option (Right to Buy) · Derivative | 18,188 | $0.00 Strike: $13.40 | $0.00 |
DisclosureSEC source: 0000899243-19-016407 · doc4.xml · derivative · entry 1 Borisy Alexis · CIK 0001319446 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,188 Underlying: Common Stock · 18,188 shares Expires 2029-06-06 F1 · derivative.exercise_date: This option shall vest and become exercisable in full upon the earlier to occur of (a) June 7, 2020 or (b) the next annual meeting of the Issuer's stockholders. Read SEC document |
| June 07, 2019 Filed Jun 11, 2019 20:59 UTC |
BONNEY MICHAEL WDirector
|
GrantStock Option (Right to Buy) · Derivative | 18,188 | $0.00 Strike: $13.40 | $0.00 |
DisclosureSEC source: 0000899243-19-016406 · doc4.xml · derivative · entry 1 BONNEY MICHAEL W · CIK 0001219016 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,188 Underlying: Common Stock · 18,188 shares Expires 2029-06-06 F1 · derivative.exercise_date: This option shall vest and become exercisable in full upon the earlier to occur of (a) June 7, 2020 or (b) the next annual meeting of the Issuer's stockholders. Read SEC document |
| March 20, 2019 Filed Mar 22, 2019 21:01 UTC |
Booth BruceDirector
|
SaleCommon Stock | 14,245 | $17.86 | $254,415.70 |
DisclosureSEC source: 0001209191-19-021014 · doc4.xml · nonDerivative · entry 3 Booth Bruce · CIK 0001451612 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold by AVA X LP in multiple transactions at prices ranging from $17.75 to $18.14, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: The shares are held directly by AVA X LP. AVA X LLC is the general partner of AVA X LP. Dr. Booth is a member of AVA X LLC and disclaims beneficial ownership of such securities held by AVF X and AVA X LP, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| March 20, 2019 Filed Mar 22, 2019 21:01 UTC |
Booth BruceDirector
|
OtherCommon Stock | 14,245 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-021014 · doc4.xml · nonDerivative · entry 2 Booth Bruce · CIK 0001451612 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 14,245 F3 · kind: Represents the shares received by AVA X LP in connection with the pro rata distribution described in footnote 1 by AVF X. F4 · ownership.nature: The shares are held directly by AVA X LP. AVA X LLC is the general partner of AVA X LP. Dr. Booth is a member of AVA X LLC and disclaims beneficial ownership of such securities held by AVF X and AVA X LP, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| March 20, 2019 Filed Mar 22, 2019 21:01 UTC |
Booth BruceDirector
|
OtherCommon Stock | 726,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-021014 · doc4.xml · nonDerivative · entry 1 Booth Bruce · CIK 0001451612 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 4,117,125 F1 · kind: Represents a pro rata distribution, and not a purchase or sale of securities, by Atlas Venture Fund X, L.P. ("AVF X") to its general partner and limited partners without additional consideration. F2 · ownership.nature: The shares are held directly by AVF X. The general partner of AVF X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. Dr. Booth is a member of AVA X LLC and disclaims beneficial ownership of such securities held by AVF X and AVA X LP, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| March 20, 2019 Filed Mar 22, 2019 21:03 UTC |
Atlas Venture Fund X, L.P.10% owner
ATLAS VENTURE ASSOCIATES X, L.P.10% owner
Atlas Venture Associates X, LLC10% owner
|
SaleCommon Stock | 14,245 | $17.86 | $254,415.70 |
DisclosureSEC source: 0001209191-19-021017 · doc4.xml · nonDerivative · entry 3 Atlas Venture Fund X, L.P. · CIK 0001628098 · 10% owner ATLAS VENTURE ASSOCIATES X, L.P. · CIK 0001742766 · 10% owner Atlas Venture Associates X, LLC · CIK 0001742765 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold by AVA X LP in multiple transactions at prices ranging from $17.75 to $18.14, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: The shares are held directly by AVA X LP. AVA X LLC is the general partner of AVA X LP. AVA X LLC disclaims Section 16 beneficial ownership of the securities held by AVA X LP, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| March 20, 2019 Filed Mar 22, 2019 21:03 UTC |
Atlas Venture Fund X, L.P.10% owner
ATLAS VENTURE ASSOCIATES X, L.P.10% owner
Atlas Venture Associates X, LLC10% owner
|
OtherCommon Stock | 14,245 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-021017 · doc4.xml · nonDerivative · entry 2 Atlas Venture Fund X, L.P. · CIK 0001628098 · 10% owner ATLAS VENTURE ASSOCIATES X, L.P. · CIK 0001742766 · 10% owner Atlas Venture Associates X, LLC · CIK 0001742765 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 14,245 F3 · kind: Represents the shares received by AVA X LP in connection with the pro rata distribution described in footnote 1 by AVF X. F4 · ownership.nature: The shares are held directly by AVA X LP. AVA X LLC is the general partner of AVA X LP. AVA X LLC disclaims Section 16 beneficial ownership of the securities held by AVA X LP, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| March 20, 2019 Filed Mar 22, 2019 21:03 UTC |
Atlas Venture Fund X, L.P.10% owner
ATLAS VENTURE ASSOCIATES X, L.P.10% owner
Atlas Venture Associates X, LLC10% owner
|
OtherCommon Stock | 726,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-021017 · doc4.xml · nonDerivative · entry 1 Atlas Venture Fund X, L.P. · CIK 0001628098 · 10% owner ATLAS VENTURE ASSOCIATES X, L.P. · CIK 0001742766 · 10% owner Atlas Venture Associates X, LLC · CIK 0001742765 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,117,125 F1 · kind: Represents a pro rata distribution, and not a purchase or sale of securities, by Atlas Venture Fund X, L.P. ("AVF X") to its general partner and limited partners without additional consideration. F2 · ownership.direct: The shares are held directly by AVF X. The general partner of AVF X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. Each of AVA X LP and AVA X LLC disclaims Section 16 beneficial ownership of the securities held by AVF X, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| February 27, 2019 Filed Feb 14, 2020 21:55 UTC |
BONNEY MICHAEL WDirector
|
GiftCommon Stock | 150,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-004667 · doc5.xml · nonDerivative · entry 1 BONNEY MICHAEL W · CIK 0001219016 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,346 Read SEC document |
| February 05, 2019 Filed Feb 7, 2019 21:19 UTC |
COOKE MICHAEL P.Chief Scientific Officer
|
GrantStock Option (Right to Buy) · Derivative | 64,000 | $0.00 Strike: $7.13 | $0.00 |
DisclosureSEC source: 0000899243-19-002870 · doc4.xml · derivative · entry 1 COOKE MICHAEL P. · CIK 0001741288 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,000 Underlying: Common Stock · 64,000 shares Expires 2029-02-04 F1 · derivative.exercise_date: This option shall vest and become exercisable in 12 equal quarterly installments beginning on January 1, 2019. Read SEC document |
| February 05, 2019 Filed Feb 7, 2019 16:16 UTC |
ISACSON CHRISTINA K.Chief Business Officer
|
GrantStock Option (Right to Buy) · Derivative | 80,000 | $0.00 Strike: $7.13 | $0.00 |
DisclosureSEC source: 0000899243-19-002865 · doc4.xml · derivative · entry 1 ISACSON CHRISTINA K. · CIK 0001741281 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2029-02-04 F1 · derivative.exercise_date: This option shall vest and become exercisable in 12 equal quarterly installments beginning on January 1, 2019. Read SEC document |
| February 05, 2019 Filed Feb 7, 2019 21:23 UTC |
ZDRAVESKI ZORANSee Remarks
|
GrantStock Option (Right to Buy) · Derivative | 80,000 | $0.00 Strike: $7.13 | $0.00 |
DisclosureSEC source: 0000899243-19-002874 · doc4.xml · derivative · entry 1 ZDRAVESKI ZORAN · CIK 0001741285 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2029-02-04 F1 · derivative.exercise_date: This option shall vest and become exercisable in 12 equal quarterly installments beginning on January 1, 2019. Read SEC document |
| February 05, 2019 Filed Feb 7, 2019 21:20 UTC |
DAVIS JOHN C. JRChief Medical Officer
|
GrantStock Option (Right to Buy) · Derivative | 70,000 | $0.00 Strike: $7.13 | $0.00 |
DisclosureSEC source: 0000899243-19-002872 · doc4.xml · derivative · entry 1 DAVIS JOHN C. JR · CIK 0001741287 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2029-02-04 F1 · derivative.exercise_date: This option shall vest and become exercisable in 12 equal quarterly installments beginning on January 1, 2019. Read SEC document |
| February 05, 2019 Filed Feb 7, 2019 21:18 UTC |
GARDNER JASONDirector · See Remarks
|
GrantStock Option (Right to Buy) · Derivative | 182,900 | $0.00 Strike: $7.13 | $0.00 |
DisclosureSEC source: 0000899243-19-002869 · doc4.xml · derivative · entry 1 GARDNER JASON · CIK 0001741286 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,900 Underlying: Common Stock · 182,900 shares Expires 2029-02-04 F1 · derivative.exercise_date: This option shall vest and become exercisable in 12 equal quarterly installments beginning on January 1, 2019. Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 21:16 UTC |
Ryan JasonSee Remarks
|
GrantStock Option (Right to Buy) · Derivative | 329,379 | $0.00 Strike: $6.00 | $0.00 |
DisclosureSEC source: 0000899243-19-000527 · doc4.xml · derivative · entry 1 Ryan Jason · CIK 0001585017 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 329,379 Underlying: Common Stock · 329,379 shares Expires 2029-01-01 F1 · derivative.exercise_date: This option shall vest and become exerciseable over four years, with 25% of this option vesting on January 1, 2020, and the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| September 25, 2018 Filed Sep 27, 2018 20:15 UTC |
RONNEBERG AMY LDirector
|
GrantStock Option (Right to Buy) · Derivative | 52,244 | $0.00 Strike: $11.67 | $0.00 |
DisclosureSEC source: 0000899243-18-025421 · doc4.xml · derivative · entry 1 RONNEBERG AMY L · CIK 0001380292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,244 Underlying: Common Stock · 52,244 shares Expires 2028-09-24 F1 · derivative.exercise_date: This option shall vest and become exercisable in 16 equal quarterly installments beginning on March 6, 2018. Read SEC document |
| June 25, 2018 Filed Jun 27, 2018 16:30 UTC |
ISACSON CHRISTINA K.Chief Business Officer
|
ConversionSeries B Preferred Stock · Derivative | 857 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-018331 · doc4.xml · derivative · entry 3 ISACSON CHRISTINA K. · CIK 0001741281 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 331 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series A Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date. F1 · price: The Series A Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: The Series A Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: The Series A Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date. Read SEC document |
| June 25, 2018 Filed Jun 27, 2018 16:30 UTC |
ISACSON CHRISTINA K.Chief Business Officer
|
ConversionSeries A Preferred Stock · Derivative | 6,670 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-018331 · doc4.xml · derivative · entry 2 ISACSON CHRISTINA K. · CIK 0001741281 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,581 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series A Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date. F1 · price: The Series A Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: The Series A Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: The Series A Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date. Read SEC document |
| June 25, 2018 Filed Jun 27, 2018 16:30 UTC |
ISACSON CHRISTINA K.Chief Business Officer
|
ConversionCommon Stock | 2,912 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-018331 · doc4.xml · nonDerivative · entry 1 ISACSON CHRISTINA K. · CIK 0001741281 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,531 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series A Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date. Read SEC document |
| June 25, 2018 Filed Jun 27, 2018 20:36 UTC |
Scadden DavidDirector
|
ConversionSeries C Preferred Stock · Derivative | 16,094 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-018341 · doc4.xml · derivative · entry 6 Scadden David · CIK 0001707715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,228 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date. F1 · price: The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date. Read SEC document |
| June 25, 2018 Filed Jun 27, 2018 20:36 UTC |
Scadden DavidDirector
|
ConversionSeries B Preferred Stock · Derivative | 6,429 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-018341 · doc4.xml · derivative · entry 5 Scadden David · CIK 0001707715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,488 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date. F1 · price: The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date. Read SEC document |
| June 25, 2018 Filed Jun 27, 2018 20:36 UTC |
Scadden DavidDirector
|
ConversionSeries A Preferred Stock · Derivative | 50,025 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-018341 · doc4.xml · derivative · entry 4 Scadden David · CIK 0001707715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 19,360 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date. F1 · price: The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date. Read SEC document |
| June 25, 2018 Filed Jun 27, 2018 20:36 UTC |
Scadden DavidDirector
|
PurchaseCommon Stock | 6,600 | $15.00 | $99,000.00 |
DisclosureSEC source: 0000899243-18-018341 · doc4.xml · nonDerivative · entry 2 Scadden David · CIK 0001707715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 228,175 F2 · shares: Reflects shares that were purchased through a directed share program in connection with the Issuer's initial public offering. Read SEC document |
| June 25, 2018 Filed Jun 27, 2018 20:36 UTC |
Scadden DavidDirector
|
ConversionCommon Stock | 28,076 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-018341 · doc4.xml · nonDerivative · entry 1 Scadden David · CIK 0001707715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 221,575 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date. Read SEC document |
| June 25, 2018 Filed Jun 27, 2018 20:36 UTC |
Atlas Venture Fund X, L.P.10% owner
ATLAS VENTURE ASSOCIATES X, L.P.10% owner
Atlas Venture Associates X, LLC10% owner
|
ConversionSeries B Preferred Stock · Derivative | 204,339 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-018342 · doc4.xml · derivative · entry 3 Atlas Venture Fund X, L.P. · CIK 0001628098 · 10% owner ATLAS VENTURE ASSOCIATES X, L.P. · CIK 0001742766 · 10% owner Atlas Venture Associates X, LLC · CIK 0001742765 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 79,079 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series A Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date. F1 · price: The Series A Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: The Series A Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: The Series A Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date. F2 · ownership.direct: The shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. Each of AVA X LP and AVA X LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| June 25, 2018 Filed Jun 27, 2018 20:36 UTC |
Atlas Venture Fund X, L.P.10% owner
ATLAS VENTURE ASSOCIATES X, L.P.10% owner
Atlas Venture Associates X, LLC10% owner
|
ConversionSeries A Preferred Stock · Derivative | 12,061,496 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-018342 · doc4.xml · derivative · entry 2 Atlas Venture Fund X, L.P. · CIK 0001628098 · 10% owner ATLAS VENTURE ASSOCIATES X, L.P. · CIK 0001742766 · 10% owner Atlas Venture Associates X, LLC · CIK 0001742765 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,667,797 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series A Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date. F1 · price: The Series A Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: The Series A Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: The Series A Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date. F2 · ownership.direct: The shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. Each of AVA X LP and AVA X LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of its pecuniary interest therein, if any. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.